ConductScience.org, home

Paper36917758

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.

Lazzeroni M and 22 others. J Clin Oncol, 2023. Cited by 94 papers, by iCite.

Cite this record

ConductScience Library. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study. Papers, record 36917758. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36917758

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.
PubMed
Journal
J Clin Oncol
PubMed
Year
2023
PubMed
Publication types
Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
94
iCite
Relative citation ratio, by iCite
8.62
iCite
Revised in PubMed
2023-06-11
PubMed

Authors23

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lazzeroni MMatteohttps://orcid.org/0000-0002-2162-4002
2Puntoni MMatteohttps://orcid.org/0000-0002-7908-0626
3Guerrieri-Gonzaga AAlianahttps://orcid.org/0000-0003-1915-1688
4Serrano DDavidehttps://orcid.org/0000-0002-2945-4108
5Boni LLucahttps://orcid.org/0000-0003-2217-4047
6Buttiron Webber TTaniahttps://orcid.org/0000-0002-3605-2828
7Fava MMariannahttps://orcid.org/0000-0001-5775-8638
8Briata IMIrene Mhttps://orcid.org/0000-0003-0767-0026
9Giordano LLivia
10Digennaro MMaria
11Cortesi LLaura
12Falcini FFabiohttps://orcid.org/0000-0002-0864-6266
13Serra PPatriziahttps://orcid.org/0000-0003-4959-579X
14Avino FFrancahttps://orcid.org/0000-0002-8128-6738
15Millo FFrancesco
16Cagossi KKatia
17Gallerani EElisa
18De Simone AAlessiahttps://orcid.org/0000-0002-1903-1611
19Cariello AAnna
20Aprile GGiuseppe

Source PubMed

See all 23 authorsDownload CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Intraductal, NoninfiltratingMajor topic
Breast NeoplasmsMajor topic
Carcinoma in SituMajor topic
Female
Humans
Tamoxifen
Follow-Up Studies
Antineoplastic Agents, Hormonal
Neoplasm Recurrence, Local

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01357772Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-upResultsYes

Source ClinicalTrials.gov

Download CSV of trials

Cited by57

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 94 citations.

PMIDTitleJournalYearIn PapersSource
42693657Discovery of ERα-Targeting Phytochemicals With In Vitro Cytotoxicity and Computational Prediction of Y537S Mutant Inhibition.Chem Biol Drug Des2026https://conductscience.org/library/papers/42693657PubMed
42684505Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study.Breast Cancer Res Treat2026https://conductscience.org/library/papers/42684505PubMed
42233150AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2026.Breast Care (Basel)2026https://conductscience.org/library/papers/42233150PubMed
42114785Impact of Tamoxifen Only After Lumpectomy for "Good-Risk" Duct Carcinoma In Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials.Int J Radiat Oncol Biol Phys2026https://conductscience.org/library/papers/42114785PubMed
42041742
Reconsidering the Interpretation of "Recurrence-Free Survival" After Mastectomy for DCIS. Comment on Sae-sim et al. Tamoxifen Reduces Breast Cancer Recurrence in Women with DCIS Who Underwent Mastectomy. Curr. Oncol. 2026, 33, 89.
Curr Oncol2026https://conductscience.org/library/papers/42041742PubMed
42001127A pilot study of a behavior-change intervention for preventive therapy among women at high risk for invasive breast cancer.BMC Med Inform Decis Mak2026https://conductscience.org/library/papers/42001127PubMed
41927957Reply to "Beyond Uptake Aligning Low-Dose Tamoxifen Adherence with Absolute Breast Cancer Risk," by Hu, Zhiping et al.Ann Surg Oncol2026https://conductscience.org/library/papers/41927957PubMed
41918186Clinical Outcomes of Lobular Carcinoma In Situ: Risk of Invasive Cancer Development.J Breast Cancer2026https://conductscience.org/library/papers/41918186PubMed
41744831High-Risk Benign Breast Lesions: An Ontario Health (Cancer Care Ontario) Recommendations Report.Curr Oncol2026https://conductscience.org/library/papers/41744831PubMed
41667737Low-dose tamoxifen ameliorates ovariectomy-induced metabolic and immune dysfunction.Geroscience2026https://conductscience.org/library/papers/41667737PubMed
41654661Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose Tamoxifen.Ann Surg Oncol2026https://conductscience.org/library/papers/41654661PubMed
41619719BRCA1 and BRCA2 carriers: Perceptions of endometrial cancer risk.Gynecol Oncol2026https://conductscience.org/library/papers/41619719PubMed
41572119Evaluating the Impact of a Surgeon-Led Ductal Carcinoma in Situ Program on Endocrine Therapy Uptake.Ann Surg Oncol2026https://conductscience.org/library/papers/41572119PubMed
41510186Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention.MedComm (2020)2026https://conductscience.org/library/papers/41510186PubMed
41495021Signaling pathways and targeted interventions for precancers.Signal Transduct Target Ther2026https://conductscience.org/library/papers/41495021PubMed
41493489RISE UP for breast cancer 2024: conference highlights & takeaways.Breast Cancer Res Treat2026https://conductscience.org/library/papers/41493489PubMed
41468356Factors Associated with Low-Dose Tamoxifen Use among Women with Atypical Hyperplasia or Lobular or Ductal Carcinoma In Situ.Cancer Prev Res (Phila)2026https://conductscience.org/library/papers/41468356PubMed
41300964Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions.Cancers (Basel)2025https://conductscience.org/library/papers/41300964PubMed
41175180Evaluating the Implementation and Maintenance of a Breast Cancer Risk-Assessment and Prevention Program.Ann Surg Oncol2026https://conductscience.org/library/papers/41175180PubMed
41002088[Systemic treatment of breast cancer: professional guideline].Magy Onkol2025https://conductscience.org/library/papers/41002088PubMed

See all 57 cited byDownload CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
TAMOXIFENCHEMBL83Results1https://conductscience.org/library/drugs/CHEMBL83

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36917758

GET https://conductscience.org/api/papers/v1/36917758/authors?page=2